 Altimmune Inc. NASDAQ: ALT shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4 was achieved at six weeks with a weekly dose of 1.8mg. 